Guardant Health Secures FDA Nod for HER2-Mutant NSCLC Diagnostic
PALO ALTO, Calif., June 11, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has approved...
Zongertinib
Advertisement
Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
Boehringer Ingelheim Highlights Strong Oncology Advances at ASCO 2026
INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...
Boehringer Ingelheim Zongertinib Shows Strong NSCLC Results
INGELHEIM, Germany, April 16, 2026 Boehringer Ingelheim has announced the publication of Phase 1b Beamion LUNG-1 trial results for...
FDA Grants Priority Approval to Hernexeos for NSCLC
WASHINGTON, D.C., February 26, 2026 The U.S. Food and Drug Administration (FDA) has granted approval to Hernexeos (zongertinib) for...
Advertisements
FDA Grants Breakthrough Therapy Designation to HERNEXEOS® for First-Line Treatment of HER2-Mutant Advanced NSCLC
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
Advertisement
